Biogen Idec and Elan won an important endorsement for Tysabri with a recommendation from Britain's cost-effectiveness watchdog--the National Institute for Health and Clinical Excellence--that the drug be made available to patients with the most severe form of the disease. Tysabri has been making a steady comeback since the therapy was derailed in early '05 after patients taking the drug developed a rare brain disease. Regulators ushered it back onto the market after adding some restrictive guidelines on its use after a large contingent of MS patients demanded access to the therapy.
- check out the release
- read the report from the Irish Times